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dopaminergic neurons in the substantia nigra and the formation of
intraneuronal inclusions called Lewy bodies, which are composed mainly
of α-synuclein (α-syn). Selegiline (Sel) is a noncompetitive monoamino
oxidase B inhibitor that has neuroprotective effects and has been
administered to PD patients as monotherapy or in combination with
L-dopa. Besides its known effect of increasing the level of dopamine
(DA) by monoamino oxidase B inhibition, Sel induces other effects that
contribute to its action against PD. We evaluated the effects of Sel on the in
vitro aggregation of A30P and wild-type α-syn. Sel delays fibril formation
by extending the lag phase of aggregation. In the presence of Sel, electron
microscopy reveals amorphous heterogeneous aggregates, including large
annular species, which are innocuous to a primary culture enriched in
dopaminergic neurons, while their age-matched counterparts are toxic. The
inhibitory effect displayed by Sel is abolished when seeds (small fibril
pieces) are added to the aggregation reaction, reinforcing the hypothesis
that Sel interferes with early nuclei formation and, to a lesser extent, with
fibril elongation. NMR experiments indicate that Sel does not interact with
monomeric α-syn. Interestingly, when added in combination with DA
(which favors the formation of toxic protofibrils), Sel overrides theress: foguel@bioqmed.ufrj.br.
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255Effects of Selegiline on α-Synuclein Aggregationinhibitory effect of DA and favors fibrillation. Additionally, Sel blocks the
formation of smaller toxic aggregates by perturbing DA-dependent fibril
disaggregation. These effects might be beneficial for PD patients, since the
sequestration of protofibrils into fibrils or the inhibition of fibril dissociation
could alleviate the toxic effects of protofibrils on dopaminergic neurons. In
nondopaminergic neurons, Sel might slow the fibrillation, giving rise to the
formation of large nontoxic aggregates.© 2010 Elsevier Ltd. All rights reserved.Introduction
The pathological characteristics of Parkinson's
disease (PD) include the preferential loss of dopa-
minergic neurons in the substantia nigra and the
formation of intraneuronal fibrillar inclusions
called Lewy bodies, which are composed mainly
of α-synuclein (α-syn).1–4 Although the precise
mechanism underlying this selective cell loss has
not yet been elucidated, α-syn aggregation is an
invariant feature of the sporadic and familial forms
of PD and has been observed in the pathogenesis
of multiple system atrophy and dementia with
Lewy bodies. These and other neurodegenerative
disorders characterized by α-syn inclusions are
collectively known as synucleinopathies.5 Further-
more, a central role of α-syn in the pathogenesis of
PD is supported by strong genetic evidence:6–10 (1)
three missense mutations in α-syn (A30P, A53T,
and E46K) are associated with autosomal-domi-
nant inherited forms of PD; (2) duplication and
triplication in a region that encompasses the α-syn
gene on chromosome 4 are sufficient to cause
familial PD; and (3) all familial PD mutations
accelerated the aggregation of α-syn in vitro, but
not necessarily fibrillation.7,11–13
Selegiline (Sel; R(−)-deprenyl) (Fig. 1a) is a
noncompetitive irreversible monoamino oxidase B
(MAO-B) inhibitor that was first synthesized as a
“psychic energizer.”14 The neuroprotective activity
of Sel became evident when it was found to be able
to block the effect of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), a neurotoxin that
induces pathological abnormalities similar to those
observed in PD patients.15–17 MPTP is oxidized to
MPP+- (the active form of the toxin) by MAO-B in
glial cells and is taken up by dopaminergic neurons,
where it leads to neuronal death by generating
reactive oxygen species (ROS) and by interfering
with mitochondria respiration and other cellular
processes.18,19 It is possible that there is an endog-
enous toxin that mimics MPP+, leading to oxidative
stress in dopaminergic neurons and ultimately to
idiopathic PD. Additionally, tyrosine hydroxylase
[involved in dopamine (DA) biosynthesis] and
monoamino oxidase (involved in DA breakdown)
both generate ROS (H2O2) as a result of their role in
DA (Fig. 1a) metabolism. Thus, inhibition of MAO-Bseems to be an attractive strategy for quelling PD
symptoms and inhibiting disease progression, since
the net effect is a decrease in the concentration of
ROS and an increase in the concentration of DA.
Sel has been administered to patients in the early
stage of PD either as monotherapy or in combination
with L-dopa.20 In the former, Sel treatment leads to a
mild anti-parkinsonian effect, thus delaying the need
for L-dopa therapy in these patients. When combined
with L-dopa, Sel potentiates the effects of L-dopa,
allowing for a reduction in its daily dose, which is a
benefit given its adverse side effects.21,22Mytilineou et
al.23 reported that aside from preventing free radical
formation through MAO-B inhibition, Sel also exerts
neuroprotection by increasing the anti-oxidant
defenses of the cells through stimulation of the
synthesis of neurotrophic factors and by modulating
the apoptotic pathway.24,25 Some of these effects are
independent of MAO-B inhibition, since they occur
in concentrations below those required to inhibit
MAO-B. However, until now, the precise mechanism
and site of action of Sel have remained uncertain. The
doses of Sel used in the treatment of patients with
parkinsonism range from 1.25 to 10 mg/day.20,26
Recently, Ono et al. demonstrated the inhibitory
effect of Sel and other anti-parkinsonian agents on
the in vitro aggregation of wild-type (WT) α-syn.27
They also demonstrated the disaggregating proper-
ties of Sel on preformed α-syn fibrils. In the present
study, we investigated the effects of Sel alone or in
combination with DA on the in vitro aggregation of
A30P andWT α-syn. The purposes of the studywere
to provide more insights into the mechanism of
action of Sel, to more closely simulate the scenario of
PD when these two compounds are administered
together as therapeutic agents, and to elucidate the
potential of Sel as an anti-fibrillogenic agent in
familial PD.
Our data show that Sel (α-syn/Sel molar ratio
≥1:0.5) inhibits the fibrillation of A30P andWT α-syn
by delaying the nucleation phase. By utilizing
bidimensional NMR, we were able to show that Sel
does not interact with any specific amino acid residue
in soluble α-syn. Experiments in primary cultures of
dopaminergic neurons demonstrated that aggregates
formed in the presence of Sel in the nucleation phase
are innocuous, while age-matched aggregates cause
cell death. Furthermore, the combination of DA Sel
Fig. 1. Effect of Sel on α-syn fibril formation. (a) Structures of Sel (R(−)-deprenyl) and DA. (b) A30P (140 μM) was
incubated at 37 -C, with stirring (185 rpm), in the absence (filled circles) or in the presence of 70 μMSel (hollow squares) or
200 μM Sel (hollow triangles) for 15 days. Fibril formation was monitored by Thio-T binding. (c) A30P (140 μM) was
incubated under aggregating conditions. After 15 h, 200 μM Sel was added to one-half of this solution (arrow, hollow
triangles), and Thio-T binding was evaluated over time. An equivalent volume of buffer was added to the control sample
(filled circles). (d) Effect of Sel on the nucleation phase of A30P aggregation. A30P (140 μM) was stirred in the absence
(filled circles) or in the presence (hollow circles) of 5k seeds at 37 -C. The aggregation of A30P in the presence of 200 μM
Sel is shown as filled triangles, while the aggregation of A30P in the presence of 200 μM Sel and 5k seeds is shown as
hollow triangles. Aggregation kinetics was monitored by Thio-T binding. (e) CD spectra of 140 μMA30P in solution (full
line) or incubated for 4 days under aggregating conditions in the absence (dotted lines) or in the presence (hollow squares)
of 200 μMSel. A long broken line shows the spectrum of soluble A30P Sel (overlapped with the spectrum of soluble A30P)
and the spectrum of Sel alone (dot/dash line). (f) WT α-syn (140 μM) was incubated under aggregating conditions for
12 days in the absence (filled circles) or in the presence (filled triangles) of 200 μMSel. Hollow circles show the aggregation
of WT protein in the presence of 5k seeds, while hollow triangles show aggregation in the presence of 200 μM Sel and 5k
preformed WT seeds.
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257Effects of Selegiline on α-Synuclein Aggregationleads to the appearance of amyloid fibrils, suggesting
that Sel counteracts the inhibitory effect of DA on
fibril formation. These data provide new insights into
the mechanisms underlying the in vivo effects of Sel
and suggest that Sel decreases the concentration of
neurotoxic protofibrils by increasing fibril formation,
even in the presence of DA. Such an effect, in addition
to Sel-mediated MAO-B inhibition, could be benefi-
cial to PD patients.
Results
Effects of Sel on the in vitro aggregation kinetics
of α-syn
In vitro, α-syn exists as an ensemble of disordered
structures.28 In the absence of mechanical agitation
or other additives, α-syn fibrillization is a very slow
process that requires incubation for weeks even at
37 °C.29,30 Interestingly, overexpression of α-syn in
cellular models of synucleinopathies is not sufficient
to drive its fibrillization in the absence of external
stimuli (i.e., exposure to free radicals andmetals; e.g.,
Fe3).31 Therefore, to investigate the aggregation
properties of α-syn in vitro in a feasible timescale,
we used micromolar concentrations of protein.32–34
This implies the use of Sel in the same concentration
range to keep the molar ratio close to 1, although it is
physiologically reasonable to assume that nanomo-
lar concentrations of Sel penetrate the intracellular
milieu when administered to PD patients. As a result
of these limitations, all our aggregation studies were
carried out at the micromolar concentrations of both
molecules. Initially, we evaluated the effects of 17
and 35 μMSel on the aggregation of 140 μMA30P α-
syn (α-syn/Sel ratios close to 1:0.1 and 1:0.2;
Supplementary Fig. 1a). At these substoichiometric
ratios, we did not observe a considerable effect of
Sel on the aggregation of α-syn after 48 or 72 h. The
same results were observed for WT α-syn (Supple-
mentary Fig. 1b; see the bar related to a α-syn/Sel
ratio of 1:0.1). Thus, all further experiments were
performed using ratios of 1:0.5 (α-syn/Sel)—the
lowest molar ratio at which Sel was stated to
be effective in inhibiting α-syn aggregation
(Supplementary Fig. 1).
Given the previous reports of Ono et al. on the effect
of Sel on the aggregation of WT α-syn,27 we decided
to focus on the disease-associated mutant A30P and
to compare it to the WT protein when the effect of Sel
on A30P appears to differ from previously reported
results onWT α-syn. This specific variant was chosen
in a first approach since it accelerates the events in the
oligomerization process of α-syn and attenuates the
helical propensity found in the N-terminal region of
the protein previously observed by NMR experi-
ments—features that were not observed with
A53T.7,35In order to evaluate if Sel would interfere with the
aggregation kinetics of A30P as it did with the
aggregation of the WT protein,27 we incubated
140 μM A30P in the absence (Fig. 1b, circles) or in
the presence of 70 μM Sel (squares) or 200 μM Sel
(triangles) under aggregating conditions. Thioflavin T
(Thio-T) binding (Fig. 1b) and turbidity (absorbance at
330 nm; data not shown) were measured periodically
during 15 days of incubation. In the absence of Sel, the
aggregation of A30P displayed a nucleation-depen-
dent polymerization profile34,36 with a short lag phase
of ~18F3 h in which no change in Thio-T binding
(Fig. 1b) or no absorbance at 330 nm (data not shown)
was detected. This result is consistentwith previously
published studies.12,37 It has been shown that in the
lag phase, small oligomers, which act as the seeds or
nuclei of the aggregation reaction, are formed.34,36
After this period, fibril growth occurs in a cooperative
manner, resulting in a large increase inThio-Tbinding
and in absorbance at 330 nm. In the presence of 70 or
200 μM Sel (α-syn/Sel molar ratio of 1:0.5 or 1:1.5),
nuclei formation was drastically delayed (Fig. 1b,
squares and triangles, respectively), and the lag phase
was extended to approximately 1.5 and 5 days,
respectively. Besides, after 6–8 days under aggregat-
ing conditions, fibrillation almost leveled off in the
control sample, while it was inhibited by ~70–80% in
the presence of 70 and 200 μMSel, suggesting that Sel
also has some effect on fibril growth inhibition.
However, after 15 days of aggregation in the presence
of Sel, the amounts of fibrils formed in the absence
and in the presence of Sel attained equal amounts (see
isolated symbols on the right of Fig. 1b). Altogether,
these results suggest that Sel inhibits the aggregation
ofA30Paswell as it inhibits the aggregation of theWT
protein,27 but its effect seems to be more specific for
nuclei formation, thus extending the lag phase of
A30P aggregation.
In order to explore more carefully the effect of Sel
on nuclei formation, we incubated 140 μM A30P
under aggregating conditions for 18 h until the
nuclei had formed. At this point, 200 μM Sel was
added to the solution (Fig. 1c, arrow, triangles).
Despite the excess amounts of Sel, it was not able to
extend the lag phase under these conditions; after
8 days of aggregation, Thio-T binding had only
slightly diminished in the sample containing Sel.
This result reinforces the idea that Sel exerts its
activity more prominently on the initial phase of
fibril formation (i.e., the nucleation phase).
Additional evidence of the effect of Sel on the
nucleation phase of A30P aggregation comes from
the experiments described in Fig. 1d. As previously
shown,36,37 addition of preformed seeds (prepared
by the fragmentation of mature fibrils by sonication)
accelerates the fibrillation process by abolishing the
nucleation phase. Figure 1d shows that the addition
of seeds (5%) to an aggregating solution of A30P
abolished the lag phase (compare the seeded curve
258 Effects of Selegiline on α-Synuclein Aggregationin hollow circles and broken line with the unseeded
curve in filled circles and continuous line). Again,
addition of Sel in a molar ratio of 1:1.5 extended the
nucleation phase to 5 days (filled triangles and
continuous line). Nevertheless, when fibrillation
was performed in the presence of Sel (1:1.5) and
5% seeds (hollow triangles and broken line), the
inhibitory effect of Sel on the nucleation of A30P was
drastically reduced, reinforcing the idea that the
major effect of Sel is on nuclei formation. Note again
that after 15 days, both seeded reactions (control and
Sel) attained equivalent Thio-T binding levels,
consistent with the idea that Sel has little effect on
the growth phase of A30P aggregation once nuclei
are formed.
Previous studies indicate that β-sheet formation
is a crucial early step in the amyloidogenesis of
α-syn38,39 and is a signature of amyloid fibril
formation. To evaluate the effects of Sel on β-sheet
formation, we performed circular dichroism (CD)
measurements (Fig. 1e). Since α-syn is unfolded in
its native state, its CD spectrum has no minimum in
the range 210–230 nm, where α-helices and β-sheets
absorb. Instead, it displays a negative minimum at
around 200–205 nm (Fig. 1e, continuous line),
indicative of disorganized random coils (calculated
as 58% of random coils). The CD spectrum of A30P
fibrils formed after 4 days under aggregating
conditions displayed a decreased negativity at
205 nm and an increased minimum at ~220 nm,
characteristic of β-sheets present in the amyloid fold
(Fig. 1e, dotted line; calculated as 58% β-sheets and
5.5% random coils).40 However, the spectrum of the
sample incubated for 4 days in the presence of Sel
(200 μM) displayed a less intense signal at 220 nm,
consistent with the presence of fewer β-sheet-rich
structures in these samples. Furthermore, the
random-coil signal also diminished, consistent
with the conversion of soluble unfolded α-syn into
a more ordered species (Fig. 1e, open squares;
calculated as 40% β-sheets). Figure 1e also presents
the CD spectrum of Sel alone (dot/dash line) and the
spectrum of soluble A30P in the presence of 200 μM
Sel (long broken line), which is superimposed on
that displayed by soluble A30P. These results
suggest that the presence of Sel does not compro-
mise or induce any structural alteration on α-syn
secondary structure.
To assess if the inhibitory effect of Sel was specific
for α-syn, we evaluated Sel activity against the yeast
prion Sup35, which is also natively unfolded, and
transthyretin (TTR), which is an amyloidogenic
β-sheet-rich homotetrameric protein. A 4-fold molar
excess of Sel (Supplementary Fig. 2, long broken
line) drastically inhibited the aggregation of Sup35
by delaying the nucleation phase and by decreasing
the total amount of fibrils at the end of the
fibrillation process. In this case, however, Sel
activity was not abolished when it was added atthe end of the lag phase (18 min, arrow), suggesting
that Sel also blocks the growth process of Sup35
fibrillation (Supplementary Fig. 2, dotted line). In
contrast, Sel was incapable of inhibiting TTR
aggregation at a TTR/Sel molar ratio of 1:1 or 1:4
(data not shown). As previously shown, aggrega-
tion of TTR is initiated from a partially unfolded
monomer, which aggregates without a lag phase.41
It is possible that the lack of a defined and/or
stable nucleus in the aggregation of TTR explains
the inefficacy of Sel as an inhibitor.
Ono et al. had already described the inhibitory
effect of Sel on the in vitro aggregation ofWT α-syn.27
However, its precise mechanism of action was not
explored in that study. In order to evaluate whether
Sel exerts its effect on WT aggregation by interfering
with nuclei formation, we performed the same
experiment presented in Fig. 1d (Sel seed addition),
butwith theWTprotein.As shown in Fig. 1f, addition
of 200 μM Sel inhibited the aggregation of WT α-syn
by~50%and extended the nucleationphase from18h
(filled circles) to ~3 days (filled triangles). As
expected, addition of 5% seeds drastically accelerated
the aggregation ofWTα-syn, abolishing the lag phase
(hollow circles). However, when 200 μM Sel was
added to a seeded aggregation reaction (hollow
triangles), its inhibitory effect was abolished, thus
confirming that Sel interferes more prominently with
nuclei formation in both WT and A30P α-syn
aggregation. It seems clear from the experiments
described in Fig. 1d (A30P) and Fig. 1f (WT) that seed
addition was much more effective in reverting the
effect of Sel in the latter case. The precise explanation
for this observation is not known at the present
moment, but one has to take into account that the
substitution at position 30 changes the important
features of the A30P aggregation reaction, such as an
increased tendency to oligomerize.12
Morphology of aggregates formed in the
presence of Sel
In order to compare the morphology of the
aggregates formed in the presence of Sel and the
morphology of the aggregates formed in the absence
of Sel, we examined the samples by negative-staining
transmission electronmicroscopy (EM) (Fig. 2). In Fig.
2a, we show the aggregates formed byA30P (140 μM)
in the absence of 200 μM Sel (−Sel; left) or in the
presence of 200 μM Sel (Sel; right). After 15 h under
aggregating conditions in the absence of Sel (Fig. 2a,
upper left), most of the fields displayed amorphous
and annular aggregates with no detectable fibrillar
structures. Most of the annular species possess
diameters of approximately 15–20 nm (arrows on
the upper left), similar to the oligomers previously
observed for this variant.32 Another population of
amorphous aggregates was also observed (dispersed
all over the grid and shown by an arrowhead). In the
Fig. 2. Morphology of the aggregates formed in the absence (−Sel) or in the presence (Sel) of 200 μM Sel. (a) A30P
aggregates formed after 15 h or 5 days under aggregating conditions. (b) Five-day-old WT aggregates. (c) Nine-day-old
A30P fibrils. In (a)–(c), the left images show the aggregates grown in the absence of Sel, while the right images show those
formed in its presence. Bars correspond to 0.2 μm. (d) A 15k SDS-PAGE of the 16-h-old aggregates of A30P (140 μM)
grown in the absence (−) or in the presence () of 200 μM Sel. (e) Same as in (d), but the aggregates here are 24 h old (lanes 1
and 2) or 48 h old (lanes 3 and 4). SeeBlueR Plus2 Pre-Stained Standard was used as molecular weight standard.
259Effects of Selegiline on α-Synuclein Aggregationsample incubated in the presence of Sel (200 μM),
amorphous coalescent aggregates were observed
after 15 h under aggregating conditions (Fig. 2a,upper right). We also detected in the latter sample
large annular aggregates with a diameter ranging
from40 to 100 nm (Fig. 2a, upper right). These annular
260 Effects of Selegiline on α-Synuclein Aggregationstructures seem to be aberrant in size and diameter
compared to those typically observed during α-syn
aggregation, which are shown on the images on the
left side of Fig. 2a. After 5 days under aggregating
conditions, the control sample exhibited mostly
fibrillar assemblies (Fig. 2a, lower left); however, in
the sample incubated in the presence of 200 μM Sel,
amorphous aggregates predominated, with some
fibrils being observable (lower right).
The morphology of the aggregates formed from
WT α-syn was also analyzed by EM (Fig. 2b). After
5 days under aggregating conditions, we observed
mostly fibers in the control sample (left), while the
aggregates formed in the presence of Sel were
predominantly heterogeneous and amorphous
(right).
The data presented in Fig. 1b show that after long
incubation times under aggregation conditions in
the absence or in the presence of Sel, the same
amount of Thio-T-binding-competent species is
formed. The EM images of Fig. 2c show that, indeed,
after 9 days under aggregating conditions, there are
large amounts of mature amyloid fibrils in the
sample incubated in the absence (left) or in the
presence (right) of 200 μM Sel.
Taken together, the EM analyses reinforce the
idea that Sel delays the aggregation of A30P and
WT α-syn most likely by inhibiting the formation
of on-pathway aggregates that constitute the nuclei
for the aggregation reaction. In the presence of Sel,
large amorphous coalescent aggregates or large
annular species are found, and these species retard
the formation of mature fibers, although the extent
of fibril formation or the Thio-T-positive species
are comparable to the control sample at long
incubation times.
Aiming to better characterize the prefibrillar
aggregates formed by α-syn in the absence or in
the presence of Sel, we analyzed their resistance to
SDS. As previously shown, the early aggregates
formed during WT α-syn fibrillogenesis are soluble
and susceptible to the conversion into monomers by
SDS. On the contrary, the late formed aggregates and
the mature fibrils precipitate but are solubilized into
a myriad of oligomers with high molecular
weights.42 Figure 2d shows the migration profiles
of the aggregates formed in the absence (left lane) or
in the presence (right lane) of 200 μMSel after 16 h of
aggregation. Note that they responded similarly to
SDS treatment, with all of them being susceptible to
the detergent. However, after 24 h of aggregation in
the absence of Sel, it is possible to detect some
aggregates that are SDS resistant (Fig. 2e, lane 1).
Interestingly, in the presence of Sel, at this time point,
only a few SDS-resistant aggregates are present (Fig.
2e, lane 2), probably because Sel delays the matura-
tion of these aggregates. After 48 h of aggregation,
SDS-resistant aggregates are present under both
conditions (Fig. 2e, lanes 3 and 4). As previouslyshown, the aggregates formed in the presence of DA
were shown to be SDS resistant since the beginning
of the aggregation reaction.42,43 Thus, we can
conclude that the aggregates formed in the presence
of Sel, despite their aberrant morphology (Fig. 2a),
respond to SDS as their counterparts grown in the
absence of Sel.
Effect of DA and Sel on A30P aggregation
Since Sel has been administered to PD patients in
combination with L-dopa,20,22 which is converted
into DA (Fig. 1a) by dopaminergic neurons, we
evaluated the combined effect of Sel and DA on the
aggregation process of A30P. Figure 3 shows Thio-T
binding to A30P (140 μM) incubated in the absence
(filled circles) or in the presence of DA (1:1 A30P/
DA) and DA Sel (1:1:1.5 A30P/DA/Sel). As has
been demonstrated previously and as has been
confirmed in the curve in hollow circles, DA inhibits
the fibrillation process of α-syn, leading to the
accumulation of protofibrils.44,45 However, the
presence of Sel partially counteracted this inhibitory
effect of DA, leading to the appearance of species
that bind Thio-T (hollow triangles). These data are
better visualized in Fig. 3b, where aggregation in the
absence of any additive was construed as 100%. DA
inhibits 87% of fibril formation, while DA Sel inhibit
aggregation by ~60%.
Figure 3c shows the morphology of the aggregates
of A30P formed in the presence of 140 μM DA after
6 days of incubation under aggregating conditions,
where only annular structures with diameters of
20–40 nm were observed. Figure 3d and e show
the aggregates of A30P formed in the presence of
140 μM DA 200 μM Sel after 2 and 6 days,
respectively. After 2 days under aggregation,
some small annular oligomers are observable
(Fig. 3d, arrows), while fibrils were observed in
the samples after 6 days (Fig. 3e).
This counteracting effect of Sel on DA activity is
intriguing, and one possible explanation for it would
be that Sel binds directly to DA, leading to
coaggregation of the two compounds. Also, Sel
could interfere with DA oxidation, abolishing its
effect on α-syn aggregation, since an oxidized state
of DA responds to its activity, as shown
previously.43 These possibilities do not seem to be
the case. Supplementary Figure 3a shows that
oxidation of DA, as measured by the increase in
absorbance at 386 nm,46 is slightly retarded in the
presence of Sel but achieves equal levels after 3–
4 days of incubation at 37 °C. Besides, we can rule out
that the two compounds coaggregate in solution
because the absorbance at 386 nm of a solution that
remained for 10 days at 37 °C after its centrifugation
or filtration is equal to that displayed by a solution
incubated with these two compounds and not
filtered or centrifuged (Supplementary Fig. 3b).
Fig. 3. Effects of DA Sel on A30P fibrillation. (a) A30P (140 μM) was incubated under aggregating conditions for
15 days in the absence of 140 μM DA (filled circles), in the presence of 140 μM DA (hollow circles), or in the presence of
DA Sel (140 μM DA 200 μM Sel; hollow triangles). Aggregation was followed by Thio-T binding. (b) Percentage of fibril
formation calculated from Thio-T binding after 6 days of incubation. Thio-T binding to A30P alone was normalized to
100%. (c–e) EM images of A30P incubated in the presence of 140 μM DA for 6 days (c), in the presence of 140 μM
DA 200 μM Sel for 2 days (d), or in the presence of 140 μM DA 200 μM Sel for 6 days (e). Bars correspond to 0.2 μm.
261Effects of Selegiline on α-Synuclein AggregationTaking all these observations together, we can
conclude that the counteracting effect of Sel on DA is
neither due to the coaggregation of both compounds
nor due to the inhibition of the formation of the
active oxidation product of DA by Sel.
Sel does not bind to unfolded monomeric α-syn
In order to obtain structural details about α-syn/
Sel interaction, we took advantage of NMR spec-
troscopy to compare the chemical shift deviations
induced by Sel binding to map the interacting
residue(s) in α-syn. For this purpose, the hetero-
nuclear single quantum coherence (HSQC) spec-
trum obtained in the absence of Sel (Fig. 4, green
spectrum) was overlaid to that obtained in the
presence of Sel (purple spectrum). The spectrum of
A30P α-syn exhibited a characteristic profile of anatively unfolded protein with limited resonance
dispersion in the proton dimension and good
dispersion in the nitrogen dimension.48,49 Upon Sel
addition (1:1 A30P/Sel), no significant chemical
shift changes were observed (Fig. 4, inset), suggest-
ing that Sel does not bind to monomeric A30P α-syn.
Even the addition of Sel at a higher molar ratio (1:5)
did not promote any considerable chemical shift
deviation (data not shown).
Sel disassembles preformed A30P fibrils
As shown previously by Li et al., DA is able to
disassemble preformed α-syn fibrils.50 In order to
probe Sel for its capability to counteract this
property of DA, we diluted preformed A30P fibrils
(A30P-F) to 10 μM and incubated them at 37 °C in
the presence of Sel (10 or 40 μM A30P-F Sel) or
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Fig. 4. Mapping α-syn interaction with Sel by NMR. Overlay of the 1H-15N HSQC spectra of A30P (350 μM) in the
absence (green spectrum) or in the presence (purple spectrum) of 350 μM Sel. The inset shows chemical shift deviations in
1H-15N HSQC related to α-syn in the presence and in the absence of Sel for the data presented in (a). The average chemical
shift changes were calculated as shown by Lendel et al.47
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Fig. 5. Sel promotes the disas-
sembly of A30P-F. (a) A30P
(140 μM) was incubated at 37 °C,
with stirring, for 15 days to pro-
duce fibrils. The fibrils were pel-
leted and diluted to 10 μM in a
solution containing 30 μM Thio-T
at 37 °C. Destabilization of these
fibrils was monitored by changes
in Thio-T fluorescence signal in the
absence (full line) or in the pres-
ence of 10 or 40 μM Sel (circles and
squares, respectively) or 40 μM
Sel 10 μM DA (triangles). (b) LS
values obtained after 12 h of
dilution of A30P fibrils in buffer
or in the presence of 40 μM Sel or
40 μM Sel 10 μM DA. This exper-
iment was performed in the ab-
s en c e o f Th i o -T t o avo id
competition between Thio-T and
the other compounds for the same
binding site.
263Effects of Selegiline on α-Synuclein Aggregationboth DA and Sel (A30P-F DA Sel) (Fig. 5a). As seen
in Fig. 5a, dilution of the fibrils in buffer alone led
to an ~20% decrease in Thio-T binding (continu-
ous line) due to the spontaneous dissociation of
the α-syn fibrils. This result is confirmed by the
decrease in the light scattering (LS) value observed
after 12 h of dilution (Fig. 5b). However, when
fibrils were diluted in the presence of Sel at an
A30P-F Sel ratio of 1:1 (circles) or 1:4 (squares),
there were 40% and 50% decreases in Thio-T
binding, respectively, suggesting that Sel induces
or promotes disassembly of the fibrils. Interestingly,
the combination of Sel and DA (triangles) blocks the
disaggregating property of Sel and of DA;50 hence,
the decrease in Thio-T binding was similar to that
seen upon fibril dilution in the absence of any
additive. The LS data shown in Fig. 5b confirm the
results of Thio-T binding. Also, since these LS
measurements were performed in the absence of
added Thio-T, we can rule out that the results
observed in Fig. 5a are not due to the competition of
Thio-T with Sel or DA for the same binding site on
the fibrils.Evaluating the cytotoxic effect of aggregates
formed in the presence of Sel and Sel DA using
cultured primary mesencephalic neurons
In a previous study, we demonstrated that
although aggregates of α-syn are intracellular in
PD, their addition to primary cultures of mesence-
phalic (dopaminergic) neurons proved to be toxic to
these cells.45 Here we used the same approach to ask
if differently aged aggregates formed in the absence
or in the presence of Sel would be toxic (see the
scheme in Fig. 6c). Toxicity was evaluated by
synaptophysin labeling and the formation of pykno-
tic nuclei, an indicator of apoptosis. Figure 6a and b
show images of synaptophysin-labeled neurons
from the midbrain of a 14-day-old mouse (E14) to
which A30P aggregates of different ages (1, 3, 4, and
5 days old) grown in the absence (Fig. 6a) or in the
presence (Fig. 6b) of Sel were added. Figure 6d
shows quantification of cell viability by the forma-
tion of pyknotic nuclei stained by 4′,6-diamidino-2-
phenylindole (DAPI). Interestingly, while the ag-
gregate species formed during the nucleation phase
Fig. 6. Aggregates formed in the presence of Sel or DA+Sel display a different toxicity to mesencephalic neurons in
culture. (a) Mesencephalic neurons from a 14-day-old embryonic (E14) mouse were maintained for 10 days in culture then
treated with 10 μM aggregates grown in the absence (a) or in the presence (b) of 200 μM Sel. Cells were labeled with β-
tubulin III (green), synaptophysin (red), and DAPI (blue). (c) Schematic representation of the experimental setup utilized
to construct this figure. (d) Percentage of viable cells as measured by nuclear fragmentation (DAPI) after the addition of
10 μMA30P aggregates grown in the absence of Sel and DA (filled circles), in the presence of 200 μM Sel (hollow circles),
or in the presence of 140 μMDA+200 μM Sel (hollow triangles). The ages of the aggregates are displayed in the abscissa.
Bars represent the meanFSD for three independent experiments performed in triplicate.
264 Effects of Selegiline on α-Synuclein Aggregationin the absence of Sel (15 h, 1 day, and 2 days old)
were progressively more toxic to mesencephalic
neurons (Fig. 6d, filled circles), the aggregates
formed during this period of time in the presence
of Sel were innocuous to these cells (hollow circles).In the control sample, as aggregates age, their
toxicity decreases (filled circles), consistent with
the hypothesis of dnontoxic fibrils.T The images in
Fig. 6a and b clearly show the toxic effect of the
aggregates formed for up to 4 days in the absence of
265Effects of Selegiline on α-Synuclein AggregationSel (Fig. 6a) in comparison to the toxic effect of the
aggregates formed in its presence (Fig. 6b), while the
images of the cells treated with 5-day-old aggregates
show a similar amount of neurons.
Our next step was to investigate the toxicity of the
aggregates formed in the presence of DA Sel to
primary mesencephalic neurons using DAPI. Al-
though not presented here, it has been shown
previously that protofibrils formed in the presence
of DA are toxic to cells in culture.45,51 As seen in
Fig. 6d (inverted triangles), the toxicity of the
aggregate species formed in the presence of
DA Sel presented a profile similar to that displayed
by the control sample (filled circles), with the
particularity that their toxicity decreases earlier.
These results are consistent with the aggregation
profile displayed in Fig. 3a (triangles). In the
presence of DA Sel, the lag phase of the aggregation
reaction persisted up to ~2d. At this time frame, a
mixture of small annular and heterogeneous aggre-
gates is formed, and it resembles those formed in
the control sample (compare Figs. 2a and 3d). These
species presented the highest toxicity (Fig. 6d). As
soon as fibrils are formed due to the counteracting
effect of Sel on DA-induced fibril inhibition, Thio-T
binding increases and toxicity decreases.
Discussion
Sel as a therapy in PD
Recently, Pålhagen et al. conducted a long-term
study demonstrating that Sel delays the progression
of the signs and symptoms of PD.20 Sel significantly
delayed the initiation of levodopa therapy; after a
5-year study, the mean dose of levodopa was 19%
higher in placebo-treated PD patients than in Sel-
treated PD patients. These results confirm the
benefits of treating PD patients with Sel, a safe and
well-tolerated drug. In spite of all its clinical
benefits, the mechanism underlying Sel neuropro-
tection remains obscure, although several hypoth-
eses have been proposed.21,25,52,53 Apart from its
selective inhibition of MAO-B and its anti-oxidant
properties, Sel prevents apoptosis in dopaminergic
neurons in MPTP-induced PD animal models.54
This anti-apoptotic effect, which is also observed
with other propargylamines, has not been ascribed
to MAO-B inhibition.55 It has been suggested that
propargylamines may rescue degenerating dopa-
minergic neurons by inhibiting cell death signal
transduction initiated from mitochondrial perme-
ability transition, which is a sudden increase in
inner-membrane permeability to proteins with a
molecular mass below 1500 Da, and may induce a
decline in mitochondrial membrane potential. For
example, rasagiline prevents mitochondrial perme-
ability transition directly and indirectly throughinduction of the anti-apoptotic protein Bcl-2 and the
glial-cell-line-derived neurotrophic factor.56 Long-
term administration of propargylamines to rats
increased the activities of the anti-oxidation enzymes
superoxide dismutase and catalase in regions of the
brain containing dopaminergic neurons.57,58
Effects of Sel on protein aggregation: The case
of α-syn
Recently, Ono et al. studied the effects of several
anti-parkinsonian agents on the in vitro aggregation of
amyloid β,59 the peptide involved in Alzheimer's
dementia. Among these agents were DA and Sel,
which effectively inhibited amyloid β fibril formation
and destabilized preformed fibrils by an unknown
mechanism.More recently, the same group evaluated
the effects of these agents on α-syn aggregation using
the WT protein as model.27 They showed that Sel
disassembles preformed α-syn fibrils in addition to
inhibiting fibrillation.
Here, we conducted a series of biophysical and
cellular studies that aimed to elucidate the molecu-
lar mechanism underlying the effects of Sel on α-syn
aggregation and on the structural properties and
stability of α-syn aggregates. We have shown that
Sel also inhibits the aggregation of A30P, a variant of
α-syn involved in a familial form of PD. Moreover,
we were able to pinpoint the nucleation phase as the
step in the A30P aggregation process at which Sel
acts preferentially (Fig. 1b–d). Experiments with the
WT protein (Fig. 1f) also suggested that this phase
was the target for Sel intervention. This conclusion
was based on the observation that Sel increases the
lag phase from 15 h to 1.5–5 days (Fig. 1b), as well as
on its inefficacy in inhibiting α-syn aggregation
when added after nuclei formation (Fig. 1c) or in
combination with preformed seeds, which act as
nuclei for fibril extension (Fig. 1d and f).
The importance of nucleation events in amyloid
formation was revisited recently by Knowles et al.60
In this study, they presented an analytical treatment
showing that the secondary event of nucleation is a
determinant for amyloid growth in the cases
studied. This secondary event of nucleation com-
prises the formation of additional nuclei coming
from fibril fragmentation. At this moment, we do
not have a robust set of data for α-syn (spanning
protein concentrations at 2 orders of magnitude) to
make this analysis.
NMR data did not reveal any specific residue to
which Sel would bind, suggesting that either Sel
does not interact with monomeric unfolded α-syn or
this interaction was not revealed by NMR experi-
ments performed here (Fig. 4). Thus, we propose
that Sel does not bind specifically to any residue in
α-syn and probably exerts its effect by binding to an
early intermediate species that is present in the
aggregation pathway of α-syn, which forms before
266 Effects of Selegiline on α-Synuclein Aggregationnucleus formation, since Sel effects are not as
prominent anymore in the presence of preformed
seeds (Fig. 1c, d, and f). This Sel-bound intermedi-
ates are then converted into aberrant aggregates as
seen by EM (Fig. 2a), but they are not off-pathway,
since their conversion into fibrils is only delayed but
not totally impeded (Fig. 1b). This proposition is
supported by the data obtained with Sup35 and
TTR, in which Sel was able to inhibit the aggregation
of the former, which depends on the formation of a
nuclei (Supplementary Fig. 2), but was ineffective in
inhibiting the aggregation of the latter, which
depends on tetramer dissociation and monomer
partial unfolding. With the data presented here, it is
not possible to propose a mechanism through which
Sel binding would lead to the formation of these
aberrant aggregates, but specific protein–protein
interactions are responsible for nuclei formation,
and they might be compromised by Sel binding to a
crucial intermediate species that is present in the
pathway of α-syn fibrillation. Sel binding probably
bypasses the formation of toxic prefibrillar species
but not of the fibrils per se, which is interesting for
PD therapy, as discussed in the text. SDS suscepti-
bility experiments (Fig. 2d and e) also revealed that
although the morphology of the prefibrillar aggre-
gates formed in the presence of Sel is different from
the morphology of those formed in its absence, their
susceptibilities to SDS solubilization were quite
similar (Fig. 2d and e), suggesting that they are
somehow structurally related but unrelated in terms
of activity (Fig. 6d).
Very recently, Di Giovanni et al. showed that
several catechol-containing compounds, which
inhibited α-syn aggregation and seeding capacity,
also did not bind to monomeric α-syn as probed by
NMR.61 In contrast, the polyphenol epigallocatechin
gallate (EGCG), which also inhibited the aggrega-
tion of α-syn (leading to the formation of off-
pathway oligomers), interacts with the backbone
of monomeric α-syn.62 Lendel et al. showed that
Congo red and lacmoid interact with the N-terminal
and central regions of α-syn, inhibiting its
aggregation.47 In conclusion, these various studies
suggest that different compounds can function as
potent α-syn aggregation inhibitors either by inter-
acting directly with the monomeric protein or by
interacting directly with an intermediate species that
is present in the pathway to fibril formation.
Sel redirects aggregation to the formation of
nontoxic oligomers
Coincubation of α-syn with 200 μM Sel for 4–
5 days led to the formation of Thio-T-negative
amorphous aggregates and larger annular-like
structures (Fig. 2). Annular-ring-like aggregates
ranging in diameter from 15 to 20 nm have been
observed previously in aggregated α-syn solutions63and constitute the major species present when α-syn
aggregates in the presence of DA.64,65 The annular
structures formed in the presence of Sel were much
larger in diameter, ranging from 40 to 100 nm (Fig.
2a). Thus, it is possible that the association of Sel and
α-syn impedes the formation of a compact annular
structure, resulting in these aberrant rings, which
were probed to be nontoxic to cultured mesence-
phalic neurons (Fig. 6b and d). Thio-T-positive
fibrils are formed in the presence of Sel over time
(Figs. 1b and d and 2c); amyloid fibrils are observed
by EM imaging amidst the presence of a massive
population of amorphous aggregates (Fig. 2).
Unfortunately, we cannot distinguish now whether
these aberrant annular structures evolve into fibrils
over time or if other species derived from them serve
as raw materials for fibril formation. It is possible
that these structures represent off-pathway aggre-
gates that reenter the pathway upon depletion of
monomers. In this case, in doing so, they delay
aggregation.
The toxicity of the amorphous aggregates
formed in the presence of Sel was assessed using
cultured mesencephalic neurons and compared to
that formed during the aggregation of A30P alone
(Fig. 6). In the absence of Sel, the intermediate
species formed are extremely toxic, while the
amorphous aggregates formed in the presence of
Sel are innocuous to the neurons in culture.
Recently, Ehrnhoefer et al. conducted an elegant
study showing that aggregation of α-syn could be
effectively inhibited by the polyphenol EGCG.62 In
the presence of EGCG, α-syn formed spherical off-
pathway oligomers that were nontoxic to cells in
culture, suggesting that small molecules can
remodel and/or redirect the aggregation process
of amyloidogenic proteins, resulting in the forma-
tion of innocuous species. In our case, Sel also led
to the formation of nontoxic aggregates and
mature fibrils, which are also nontoxic (Fig. 6b
and d). However, as mentioned previously, further
studies are required to determine whether these
aggregates are on-pathway or off-pathway.
The counteracting effect of Sel on DA-induced
protofibril formation
In the present study, the novel effect of DA Sel
combination on A30P fibril formation was evaluat-
ed. This approach is relevant because it mimics what
happens when Sel is administered to PD patients in
combination with L-dopa, at least in terms of α-syn
aggregation. As mentioned previously, several
groups have shown that by-products of DA and
L-dopa oxidation inhibit α-syn fibril formation,
leading to the accumulation of small, spherical, and
annular aggregates, which are also called protofibrils.
Protofibrils are known to be very toxic to cells in
culture.66,67 We show here that inhibition of A30P
Fig. 7. Proposed model for Sel action on α-syn fibrillogenesis. α-Syn is a natively unfolded protein. (a) Under
aggregating conditions, the protein undergoes aggregation through the formation of toxic nuclei that act as seeds for
fibrillation. (b) In the presence of DA, fibrillation is inhibited and annular, and toxic species are formed. (c) In the presence
of Sel, nucleation is retarded, giving rise to the appearance of amorphous and larger annular aggregates, which are
nontoxic to neurons in culture. (d) In the presence of both Sel DA, fibril formation is restored to some extent. The early
prefibrillar aggregate species formed in the presence of Sel DA were shown to be toxic to mesencephalic neurons in
culture. Their toxicity diminishes as they age, but earlier than that of their age-matched counterparts.
267Effects of Selegiline on α-Synuclein Aggregationfibril formation by DA is counteracted by Sel, leading
to the formation of some mature fibrils (Fig. 3). This
result per se points to the potential benefit of a
combined therapy in PD disease, since mature fibrils
are now believed to be less toxic than small
aggregates. The precise mechanism behind the
counteracting effect of Sel on DA-induced protofibril
formation is not known at the present moment.
Possible explanations would be the coaggregation of
the two compounds, which would prevent DA fromexerting its effect, or a direct effect of Sel on the
oxidation of DA, which would block the formation of
the oxidized active species of DA. The results
presented in Supplementary Fig. 3 seem to exclude
these possibilities. It has beenproposed thatDAexerts
its effect by forming covalent adducts between the
orthoquinone derivative of DA and α-syn,44 which
causes the accumulation of covalently modified
protofibrils (annular aggregates) that are unable to
fibrillate. As shown here by NMR, Sel does not
268 Effects of Selegiline on α-Synuclein Aggregationspecifically bind to soluble α-syn (Fig. 4), but
aberrant annular structures are formed in its
presence. Therefore, both DA and Sel favor the
formation of annular aggregates; those formed in the
presence of the former are smaller, off-pathway, and
toxic, while those formed in the presence of the latter
are larger, on-pathway, and nontoxic to cell lines in
culture. When aggregation is performed in the
presence of DA and Sel, some amyloid fibrils appear
after 6 days under aggregating conditions (Fig. 3d),
but some annular aggregates still persist. Thus, it is
possible that the reminiscent annular aggregates are
those formed by the DA/α-syn adduct, while the
fibrils observed are formed from the soluble α-syn
that evades this interaction, probably caused by the
presence of Sel, which favors annular on-pathway
aggregates. Interestingly, the early aggregates
formed in the presence of Sel DA were shown to
be as toxic as the aggregates formed in the absence
of any addition; however, as soon as aggregation
proceeds and fibrils are formed, toxicity decreases,
but only when DA and Sel are present. This result is
also very interesting because the annular aggregates
formed in the presence of DA (early and late)
are very toxic to cells in culture, as previously
shown.44,66,68Conclusions and Implications for PD
A schematic depiction summarizing the main
findings of this study is presented in Fig. 7. Natively
unfolded α-syn initially forms small nuclei that seed
aggregation (nucleation phase; pathway A). These
nuclei, which are toxic, are extended by the
incorporation of monomers or other species to
form mature amyloid fibrils (extension phase). In
the presence of DA (pathway B), fibril formation is
drastically inhibited, leading to the accumulation of
annular toxic aggregates, which could explain the
selective cell loss in PD. In the presence of Sel
(pathway C), a heterogeneous population of aggre-
gates, mostly composed of amorphous and aberrant
large annular structures, is formed. These aggre-
gates, which appear to be less toxic to mesencephalic
neurons in culture, delay fibril formation, thus
expanding the nucleation phase. However, over
time, these aggregates evolve into fibrils by possibly
serving as a source of monomers or by becoming
amyloid fibrils themselves. In the presence of Sel DA
(pathway D), annular and heterogeneous oligomers
are formed during the nucleation phase, but some
fibrils are observed even though DA inhibits fibril
formation. These early aggregates formed in the
presence of DA Sel were shown to be toxic to the
cells, while the late aggregates were not. Although
Sel displays multiple effects when taken by PD
patients, the data presented herein disclose a novel
mechanism of action (i.e., its effect on α-synaggregation and fibril formation) that has implica-
tions for PD therapy.
In dopaminergic neurons, the presence of DA
would lead to the formation of protofibrils, which
have been shown to be more toxic to neurons than
the mature fibrils. While DA favors the initial steps
of fibril formation leading to the accumulation of
toxic protofibrils, Sel drives fibril formation in the
presence of DA but inhibits fibrillization in the
absence of DA. In addition, Sel was able to partially
counteract the fibril-disassembling properties of DA
(Fig. 5), which can lead to the generation of smaller
toxic species. Together, these findings suggest that
Sel could act as a detoxifying agent by removing
toxic protofibrils via enhancement of their conver-
sion into amyloid fibrils, thus sparing the dopami-
nergic neurons from the toxic effects of these
aggregates. These findings suggest that administra-
tion of Sel, in combination with DA, would be
beneficial to PD patients by favoring fibril forma-
tion. In nondopaminergic neurons, Sel slows the
fibrillation process of α-syn, probably by forming
large amorphous nontoxic aggregates that evolve
into fibrils over time.
Taken together, the data presented here provide
new insights into the beneficial mechanism that
operates when Sel and L-dopa are administered to
patients with parkinsonism. Further in vivo studies
and analysis of clinical data are necessary to test this
hypothesis. To our knowledge, this is the first report
in which the combined effect of Sel and DA on the in
vitro aggregation of the α-syn A30P variant was
evaluated, with possible correlations to their use in
PD treatment.Materials and Methods
α-Syn fibrillogenesis
Recombinant α-syn (A30P or WT) was expressed and
purified as previously described.29 Solutions of 140 μM
A30P or WT in buffer A [10 mM Tris, 100 mM NaCl, and
0.05% sodium azide (pH 7.4)] were incubated at 37 °C,
with shaking at 185 rpm, to allow fibril formation. For
cell viability assays, the samples were incubated in
buffer A without sodium azide and filtered in a sterile
0.22-μm filter. Fibrillogenesis was monitored by mea-
surement of the absorbance of the solution at 330 nm, as
well as by Thio-T binding, until a steady state had been
reached. Aggregation in the presence of DA was per-
formed as described by Conway et al.44 and Li et al.50
Briefly, 140 μM A30P was incubated in the presence of
an equimolar concentration of DA in buffer A and
allowed to aggregate as described above. To test the
effect of Sel (R(−)-deprenyl; Sigma Chemical Co.) and/or
DA (Sigma Chemical Co.) on α-syn aggregation, we
incubated 140 μM A30P in the presence of each of these
compounds at the concentrations stated in the legend to
each experiment.
269Effects of Selegiline on α-Synuclein AggregationAggregation of Sup35 and TTR
Soluble WT Sup35 was prepared as described previ-
ously by Serio et al.69 Concentrated Sup35 was diluted at
least 200-fold into phosphate buffer [5 mM potassium
phosphate and 150 mM NaCl (pH 7.4)] to a concentration
of 0.5 μM. Aggregation was performed with microstir bars
at 25 °C under constant agitation (60 rpm) using 20 μM
Thio-T binding as an indicator of fibril formation. Sel was
added to the aggregation solutions as stated in Supple-
mentary Fig. 2. For TTR aggregation, 3.5 μM TTR was
incubated at 37 °C for 72 h in 50 mM sodium acetate,
100 mMKCl, and 0.05%NaN3 (pH 4.4) in the absence or in
the presence of 5 or 14 μM Sel. The aggregation was
measured by the turbidity at 330 nm.
DA oxidation
To assay the oxidation of DA in the absence or in the
presence of Sel, we incubated the compounds at 37 °C and
measured the optical density at 386 nm as described by
Klegeris et al.46
Thio-T binding
The extent of aggregation was evaluated by Thio-T
binding. In the case of α-syn, suspensions containing the
aggregated proteins were diluted to 1 μM and mixed with
20 μM Thio-T (Sigma Chemical Co.) prepared in 50 mM
glycine (pH 8.5) in a total volume of 600 μl. Thio-T binding
was evaluated by measuring the increase in fluorescence
spectral area and the intensity at 482 nm after excitation of
the sample at 450 nm and collection of emission spectra
from 465 to 570 nm. The results of Thio-T binding are
expressed as the means of at least two separate experi-
ments, and the data were fitted using a sigmoidal
regression of three parameters.
Circular dichroism
CD spectra were recorded in a Jasco-715 spectro-
polarimeter (Jasco, Tokyo, Japan). Buffer A (without
NaN3) was used as baseline and subtracted from the
protein spectra. The protein was diluted to a final
concentration of 70 μM in buffer A. Following its dilution,
the solution was transferred to a 2-mm quartz cuvette, and
CD spectra were recorded from 195 to 260 nm at 25 °C.
Secondary structural content was calculated under each
condition with the algorithm Contin or k2d70 using the
reference set SP175‡.71–73
SDS-PAGE analysis of the aggregates
A30P (140 μM) was incubated in the absence or in the
presence of 200 μM Sel under aggregating conditions.
After the indicated time periods, 200-μl aliquots were
collected, lyophilized, and resuspended in 50 μl of SDS
sample buffer. Twenty microliters of each sample was‡http://dichroweb.cryst.bbk.ac.ukloaded in 15% SDS-PAGE, and the bands were visualized
with silver staining.
NMR experiments
Samples for NMR experiments were prepared by
diluting lyophilized 15N-labeled protein directly in
sample buffer [10 mM phosphate buffer, 100 mM NaCl
(pH 7.4), and 10% D2O] at a final concentration of
350 μM in the absence or in the presence of Sel. Large
aggregates were removed by centrifugation at 11,000g
for 10 min. All NMR samples were prepared in an ice
bath to minimize protein aggregation. All experiments
were performed at the 1H NMR frequency of 800.4 MHz
using a Bruker DRX 800-MHz narrow bore. The spectra
were acquired at 10 °C. For samples incubated in the
presence of Sel, the compound was added to a solution
containing an uniformly 15N α-syn molar ratio of 1:1;
1:2, or 1:5. Spectra were processed with topspin and
analyzed using the 15N and 1H chemical shift assign-
ments previously established by Eliezer et al.48
Disassembly of A30P fibrils induced by Sel, DA,
or DA Sel
Solutions containing 140 μM A30P were incubated for
15 days under aggregating conditions. Then, the fibrils
were centrifuged and resuspended in buffer A. After
measuring the concentration of protein (OD280), we
diluted the fibrils to 10 μM in buffer A with either DA
(10 μM), Sel (10 or 40 μM), or a combination of DA Sel
(10 40 μM) in a final volume of 1500 μl and gently stirred
them at 37 °C. To evaluate the extent of A30P fibril
disassembly promoted by these compounds, we followed
Thio-T binding with respect to time, as stated above. In the
experiments where LS was measured, the fibrils were
incubated with the compounds in the absence of Thio-T.
All results are expressed as the mean of at least three
separate experiments. The LS data were evaluated
statistically with analysis of variance (Tukey's multiple
comparison test) using the software Prism (GraphPad
Software, Inc., San Diego, CA).
Transmission EM
Samples were adhered to a carbon-coated grid, blotted
to remove excess material, and stained for 2 min with a 2%
solution of uranyl acetate prepared in water. Images were
digitally collected with a Jeol 1200 electron microscope
(Jeol Ltd., Tokyo, Japan) operating at 60 kV.
Primary neuron cultures
Neurons from the midbrain of 14-day-old Swiss mice
(E14)were prepared as previously described.74 All animals
were kept under standard laboratory conditions in
accordance with National Institutes of Health guidelines.
Mice anesthetized by hypothermia were decapitated; their
brain structures were removed, and their meninges were
carefully stripped off. Dissociated cells were plated on
coverslips coated with polyornithine (1.5 mg/ml; Sigma
Chemical Co.) in serum-free neurobasal medium
270 Effects of Selegiline on α-Synuclein Aggregationsupplemented with B27 (Invitrogen, Carlsbad, CA). For
immunocytochemistry assays, cells were plated on poly-
ornithine-treated glass coverslips. The cultures were
incubated at 37 °C in a humidified 5% CO2 and 95% air
chamber for 10 days.
Immunocytochemistry
Immunocytochemistry was performed as previously
described by Romão et al.74 Briefly, cultured cells were
fixed with 4% paraformaldehyde for 20 min and permea-
bilized with 0.2% Triton X-100 for 5 min at room
temperature. After permeabilization, the cells were
blockedwith 10%normal goat serum (Vector Laboratories,
Inc., Burlingame, CA) in phosphate-buffered saline (PBS)
(blocking solution) for 1 h, followed by an overnight
incubation with specified primary antibodies diluted in
blocking solution at room temperature. The primary
antibodies were polyclonal anti-human β-tubulin III
(1:800; Covance) and monoclonal anti-synaptophysin
(1:200; Chemicon International). Monoclonal anti-tyrosine
hydroxylase antibody (1:100; Sigma Chemical Co.) was
used to quantify dopaminergic neurons and accounted for
95% of the cells in culture. After the incubation of the
primary antibodies, the cellswere extensivelywashedwith
PBS/10% normal goat serum and incubated with second-
ary antibodies for 1 h at room temperature. Secondary
antibodies were conjugated with fluorescein isothiocya-
nate or Alexa (sheep anti-mouse; 1:400; Sigma Chemical
Co.). Nuclear DNAwas counterstainedwith 0.1 μg/ml 4,6-
diamidino-2-phenylindole (DAPI; Sigma Chemical Co.)
for 5 min at room temperature, washed with PBS, and
mounted on fluorescence medium. Negative control
samples were performed by omitting the primary anti-
bodies during staining. In all cases, no reactivity was
observed when the primary antibodies were omitted.
Neurotoxicity assays
After 10 days of incubation, neuron cultures were
treated with A30P aggregates of different ages (15 h, 1 day,
2 days, 3 days, and 4 days). The toxic effects of these
aggregates (at a concentration of 10 μM) were evaluated
after 24 h of incubation in neuronal cell cultures. Toxicity
was evaluated by analyzing nuclear fragmentation with
DAPI, as described above. Randomly chosen fields were
examined and counted in a Nikon Eclipse TE300
microscope (Nikon, Kanagawa, Japan). Five different
fields (~200 cells/field) were examined per well, and
three cultures were used under each experimental
condition. Buffer was used as control.
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